期刊
CURRENT ONCOLOGY REPORTS
卷 19, 期 5, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-017-0593-6
关键词
Castration-resistant prostate cancer; Neuroendocrine prostate cancer; Small-cell prostate cancer; Aggressive variant; Androgen indifference; Androgen-independent prostate cancer
类别
资金
- Millennium/Takeda
- Abbvie/Stemcentryx
- Astellas/Medivation
- Janssen
Metastatic castration-resistant prostate cancer (CRPC) is associated with substantial clinical, pathologic, and molecular heterogeneity. Most tumors remain driven by androgen receptor (AR) signaling, which has clinical implications for patient selection for AR-directed approaches. However, histologic and clinical resistance phenotypes can emerge after AR inhibition, in which the tumors become less dependent on the AR. In this review, we discuss prostate cancer variants including neuroendocrine (NEPC) and aggressive variant (AVPC) prostate cancers and their clinical implications. Improvements in the understanding of the biologic mechanisms and molecular features underlying prostate cancer variants may help prognostication and facilitate the development of novel therapeutic approaches for subclasses of patient with CRPC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据